ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

efpeglenatide

Also written as “HM11260C”, “Efpeglenatide SAR439977” and “efpeglenatide (SAR439977)”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus, led by 2 companies.

Drug pageEfpeglenatide: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 21, 201713 company-led studies, 1 open or runningNext primary completion: Nov 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hanmi Pharmaceutical91 open or runningphase 3since Nov 21, 2017Mar 23, 2010Nov 2027phase 3 · NCT07379333
Sanofiits history only40 open or runningphase 3since Apr 5, 2018Apr 5, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hanmi Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 23, 2010First study: phase 1 study in HealthyFirst studyNCT01093729 · 41 enrolled
  2. Oct 4, 2011Phase 2 study in Diabetes MellitusNCT01452451 · 72 enrolled · United States
  3. Jan 30, 2014Phase 2 study in Diabetes Mellitus, Type 2NCT02057172 · 254 enrolled · United States
  4. Feb 5, 2014Phase 1 study in Diabetes MellitusNCT02059564 · 44 enrolled · United States
  5. Feb 24, 20142 phase 2 studiesNCT02081118, NCT02075281
  6. Nov 21, 2017Phase 3 study in Diabetes Mellitus, Type 2NCT03353350 · 406 enrolled · United States, Germany, Poland and more
  7. Dec 8, 2023Phase 3 study in ObesityNCT06174779 · 448 enrolled · South Korea
  8. Jan 23, 2026Phase 3 study in Diabetes Mellitus, Type 2NCT07379333 · 118 planned · South Korea

Ahead

  1. Nov 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07379333

TargetBeta

GLP1R →read by rule
“Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
zenagamtideNovo Nordiskphase 336
survodutideBoehringer Ingelheimphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
brenipatideEli Lillyphase 319

Studies

All 9 Hanmi Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07379333Diabetes Mellitus, Type 2 · South Korea3RecruitingNov 2027118
NCT06174779Obesity · South Korea3CompletedAug 14, 2025448
NCT03353350Diabetes Mellitus, Type 2 · United States, Germany, Poland and more3CompletedJan 29, 2020406
NCT02075281Obesity · United States2CompletedJan 2015297
NCT02081118Diabetes Mellitus, Type 2 · United States2CompletedMar 2015209
NCT02059564Diabetes Mellitus · United States1UNKNOWNOct 201444
NCT02057172Diabetes Mellitus, Type 2 · United States2CompletedOct 2014254
NCT01452451Diabetes Mellitus · United States2CompletedJun 201372
NCT01093729Healthy1CompletedOct 201041

How it is read

Names in the registry

  • “HM11260C”, 12 entries
  • “Efpeglenatide SAR439977”, 2 entries
  • “efpeglenatide (SAR439977)”, 1 entry
  • “Efpeglenatide”, 1 entry
  • “Efpeglenatide (SAR439977)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.